Drugs / LVRNA012
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05549206 | Apr 2023 | Orthocoronavirinae infectious disease | AIM Vaccine Co., Ltd. | Unknown | No outcome recorded |
| — | NCT05745545 | Jan → Sep 2023 | COVID-19 | AIM Vaccine Co., Ltd. | Unknown | Met primary |
| — | NCT05550142 | Sep → Dec 2022 | COVID-19 | AIM Vaccine Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LVRNA012 | “A Preliminary Exploratory Cohort Study to Evaluate Safety, Tolerability and Immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in Participants Aged 18...” NCT05550142 ↗2“A Cohort Study to Evaluate Safety and Immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in Participants Aged 18 Years and Over in China” NCT05549206 ↗ “SARS-CoV-2 mRNA vaccine (Omicron BA.5) LVRNA012 given as the booster in immunized but SARS-CoV-2 infection-free adults in China.” PMID 38903523 ↗ Jun 2024 |
| Known as | SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine | “A Cohort Study to Evaluate Safety and Immunogenicity of SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012) in Participants Aged 18 Years and Over in China” NCT05549206 ↗ |
| Modality | Messenger RNA (mRNA) | “SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine (LVRNA012)” NCT05550142 ↗ |
| Route | Intramuscular | “Two doses were administered by intramuscular injection, 28 days apart” NCT05550142 ↗ |